Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States

Purpose

To examine the effectiveness of the recombinant zoster vaccine for preventing herpes zoster ophthalmicus in the general US population.

Design

Retrospective, observational cohort study.

Participants

Individuals enrolled in the OptumLabs® Data Warehouse (OLDW) (OptumLabs, Cambridge, MA) who were age-eligible for herpes zoster vaccination (≥50 years old) from 2018 through 2019. OLDW is a longitudinal, de-identified administrative claims and electronic health record database of patients in the United States with commercial insurance, Medicare Part D or Medicare Advantage.